Autologous stem-cell transplant plus rituximab for newly diagnosed mantle cell lymphoma: Up-date of a phase II trial

被引：0
作者：
Hicks, L
Mangel, J
Connors, J
Buckstein, R
Leitch, H
Imrie, K
Crump, M
Spaner, D
Pennell, N
Nagy, T
Boudreau, A
Berinstein, N
机构：
[1] Sunnybrook & Womens Coll Hosp, Toronto, ON, Canada
[2] London Hlth Sci Ctr, London, ON, Canada
[3] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
454
引用
收藏
页码：170 / 170
页数：1
相关论文
共 50 条
  • [31] A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma
    Dreyling, Martin
    Tam, Constantine S.
    Wang, Michael
    Smith, Stephen D.
    Ladetto, Marco
    Huang, Huiqiang
    Novotny, William
    Co, Melannie
    Romano, Alfredo
    Holmgren, Eric
    Huang, Jane
    Le Gouill, Steven
    FUTURE ONCOLOGY, 2021, 17 (03) : 255 - 262
  • [32] Complete clinical and molecular remissions can be achieved following autologous stem cell transplantation in combination with Rituximab immunotherapy for the treatment of newly diagnosed mantle cell lymphoma.
    Mangel, J
    Buckstein, R
    Imrie, K
    Spaner, D
    Crump, M
    Tompkins, K
    Pennell, N
    Reis, M
    Romans, R
    Robinson, JB
    Richardson, P
    Lima, A
    Pavlin, P
    Boudreau, A
    Nagy, T
    Berinstein, NL
    BLOOD, 2001, 98 (11) : 677A - 677A
  • [33] Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients
    Le Gouill, Steven
    Morschhauser, Franck
    Bouabdallah, Kamal
    Cartron, Guillaume
    Casasnovas, Olivier
    Gastinne, Thomas
    Chevallier, Patrice
    Rossi, Cedric
    Tchernonog, Emmanuelle
    McCulloch, Rory
    Herbaux, Charles
    Chiron, David
    Callanan, Mary
    Rule, Simon
    BLOOD, 2019, 134
  • [34] Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma
    Thomas, Alissa A.
    Abrey, Lauren E.
    Terziev, Robert
    Raizer, Jeffrey
    Martinez, Nina L.
    Forsyth, Peter
    Paleologos, Nina
    Matasar, Matthew
    Sauter, Craig S.
    Moskowitz, Craig
    Nimer, Stephen D.
    DeAngelis, Lisa M.
    Kaley, Thomas
    Grimm, Sean
    Louis, David N.
    Cairncross, J. Gregory
    Panageas, Katherine S.
    Briggs, Samuel
    Faivre, Geraldine
    Mohile, Nimish A.
    Mehta, Jayesh
    Jonsson, Philip
    Chakravarty, Debyani
    Gao, Jianjiong
    Schultz, Nikolaus
    Brennan, Cameron W.
    Huse, Jason T.
    Omuro, Antonio
    NEURO-ONCOLOGY, 2017, 19 (10) : 1380 - 1390
  • [35] Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189).
    Inwards, David James
    Hillman, David. W.
    Fishkin, Paul A.
    White, William L.
    Morton, Roscoe F.
    Dakhil, Shaker R.
    Nikcevich, Daniel A.
    Wender, Donald B.
    Fitch, Tom R.
    Kurtin, Paul J.
    BLOOD, 2006, 108 (11) : 777A - 777A
  • [36] R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma
    Omuro, Antonio
    Correa, Denise D.
    DeAngelis, Lisa M.
    Moskowitz, Craig H.
    Matasar, Matthew J.
    Kaley, Thomas J.
    Gavrilovic, Igor T.
    Nolan, Craig
    Pentsova, Elena
    Grommes, Christian C.
    Panageas, Katherine S.
    Baser, Raymond E.
    Faivre, Geraldine
    Abrey, Lauren E.
    Sauter, Craig S.
    BLOOD, 2015, 125 (09) : 1403 - 1410
  • [37] A randomized phase II trial of maintenance versus consolidation bortezomib therapy following aggressive chemoimmunotherapy and autologous stem cell transplant for previously untreated mantle cell lymphoma
    Kaplan, L. D.
    Jung, S.
    Johnson, J. L.
    Linker, C. A.
    Byrd, J. C.
    Stock, W.
    Hsi, E. D.
    Cheson, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Lawrence E. Garbo
    Patrick J. Flynn
    Margaret A. MacRae
    Mary A. Rauch
    Yunfei Wang
    Kathryn S. Kolibaba
    Investigational New Drugs, 2009, 27 : 476 - 481
  • [39] Phase II trial of bortezomib in mantle cell lymphoma
    Belch, A
    Kouroukis, CT
    Crump, M
    Sehn, L
    Gascoyne, R
    Klasa, R
    Powers, J
    Eisenhauer, E
    BLOOD, 2004, 104 (11) : 175A - 176A
  • [40] Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma
    Garbo, Lawrence E.
    Flynn, Patrick J.
    MacRae, Margaret A.
    Rauch, Mary A.
    Wang, Yunfei
    Kolibaba, Kathryn S.
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (05) : 476 - 481
12345